D&D Pharmatech
Financials
Valuation Metrics
D&D Pharmatech's Market Cap is ₩2.1T. At end of 2025 it was ₩4.2T. Ranked #208 of 2,421 in KR market (top 9%), #42 of 1,640 on KOSDAQ (top 3%), #20 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.06T KRW | KR#208/2,421 Sec#20/231 |
| Revenue | 2.75B KRW | KR#2,374/2,421 Sec#209/231 |
| Net Income | -21.75B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 97.54B KRW | KR#1,805/2,421 Sec#141/231 |
| Net Assets | 78.98B KRW | KR#1,598/2,421 Sec#129/231 |
| Employees | 24 | KR#2,231/2,421 Sec#209/231 |
| Value | ||
| P/B | 26.06x | KR#2,406/2,421 Sec#226/231 |
| P/S | 748.29x | KR#2,410/2,421 Sec#225/231 |
| FCF Yield | -1.03% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -27.54% | KR#2,159/2,421 Sec#170/231 |
| ROA | -22.30% | KR#2,263/2,421 Sec#183/231 |
| Op. Margin | -1367.89% | KR#2,385/2,421 Sec#217/231 |
| Revenue Growth | -62.42% | KR#2,311/2,421 Sec#208/231 |
| Financial Health | ||
| Debt Ratio | 23.50% | KR#454/2,421 Sec#53/231 |
| Total Debt | 2.54B KRW | KR#1,884/2,421 Sec#183/231 |
| FCF | -21.20B KRW | KR#1,905/2,421 Sec#181/231 |
| Cash | 32.88B KRW | KR#950/2,421 Sec#63/231 |
| Performance | ||
| 1Y Return | 8.67% | KR#584/2,421 Sec#36/231 |
| 1M Return | -22.72% | KR#2,320/2,421 Sec#214/231 |
| From 52W High | -61.49% | KR#1,909/2,421 Sec#152/231 |
| 1Y MDD | -59.62% | KR#1,461/2,421 Sec#116/231 |
| Trading | ||
| Volume | 440,232 shares | KR#261/2,421 Sec#15/231 |
| Trading Value | 19.92B KRW | KR#164/2,421 Sec#10/231 |
| Foreign Own. | 10.20% | KR#471/2,421 Sec#39/231 |
| Per Share | ||
| EPS | -475 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,723 KRW | KR#2,136/2,421 Sec#179/231 |
Company Info
D&D Pharmatech, established in 2014 and listed on KOSDAQ in 2024, holds subsidiaries such as Neuraly Inc., Valted Seq Inc., and P4 Microbiome Inc. The company researches and develops new drugs for metabolic, neurodegenerative, and fibrotic diseases using technologies like GLP-1, with a diverse pipeline including oral obesity treatments. Leveraging new drug development capabilities through drug delivery technology, it advances its business via technology transfer and co-development with global partners. D&D Pharmatech is headquartered in Seongnam-si, Gyeonggi-do.